Coronary artery disease is a global health problem

Management of CAD

Management of CAD includes lifestyle changes, medical therapies, medical procedures and surgery, in addition to cardiac rehabilitation. 1-3

Myocardial perfusion imaging

SPECT MPI performed during stress and at rest is an established method for diagnosing CAD, assessing risk of future cardiac events and informing treatment decisions.1

Fractional flow reserve

FFR is helpful as an adjunct to coronary angiography in guiding therapeutic decision making in CAD and FFR-guided revascularization, and is the gold standard for evaluating stenotic significance (Figure 1).1

Mode of Action

Rapiscan® (regadenoson) is the first and only selective A2A adenosine receptor agonist licensed for cardiac functional imaging.1

Clinical efficacy

Rapiscan is indicated for myocardial perfusion imaging (MPI) and Fractional Flow Reserve (FFR) examinations with results comparable with adonesine.1

Easy to administer

Rapiscan is delivered into a single, fixed dose with no need for infusion pump and weight-based dosing adjustment.1

Improved tolerability over adenosine

Well tolerated, with adverse events mostly mild and transient.1 Several studies suggest that Rapiscan has a favorable side-effect profile in comparison with adenosine.1,2

Administration in asthmatic and COPD patients

Rapiscan can be used in patients with pulmonary conditions, based on data derived from MPI clinical settings.1
case studies demonstrating the use of rapiscan in the measurement of ffr
Rapiscan is a selective A2A receptor agonist approved for the measurement of FFR.1 The following two case studies illustrate the efficacy and tolerability of Rapiscan in the measurement of FFR when evaluating the functional significance of stenosis in patients with suspected CAD.

Case study 1

FFR using Rapiscan in a 44-year-old female patient with stenosis and angina on moderate exertion Case study courtesy of Professor Nico Pijls

Case study 2

FFR using Rapiscan in a 70-year-old male patient with stenosis in the LAD Case study courtesy of Professor Nico Pijls

Fast Facts

  • Coronary artery disease (CAD) is the leading cause of death among cardiovascular diseases, accounting for ~20% of deaths each year in both sexes.1
  • Rapiscan is a selective A2A receptor agonist which effectively achieves maximal hyperemia during MPI and FFR assessment.2
  • Rapiscan can induce maximal hyperemia in 30 seconds enabling fast protocols in MPI and FFR assessment.2
  • Rapiscan is administered as a single fixed injection into a peripheral vein; no dose adjustments are required for bodyweight, elderly, renal or hepatic insufficiency.2
  • The only approved hyperaemic pharmacological stress agent for the measurement of fractional flow reserve (FFR).2
  • Rapiscan maintains hyperemia from ~3 minutes to more than 10 minutes2
  • Rapiscan is well tolerated2 and is associated with lower degree AV block than adenosine.3
  • Rapiscan can be used, with caution, in asthmatic patients and those with chronic obstructive pulmonary disease (COPD).2

1. European Heart Network. European Cardiovascular Disease Statistics 2017. Available at: (Last accessed March 2022).
2. GE Healthcare. Rapiscan Summary of Product Characteristics, December 2021.
3. Azzouz MS et al. J Am Coll Cardiol 2015; 66(15); B118–B119.


Prescribing Information

Please see Rapiscan Prescribing Information for United Kingdom

Please see Myoview Prescribing Information for United Kingdom

Adverse events should be reported.
Reporting forms and information can be found at
Adverse events should also be reported to GE Healthcare at

01-2022 JB01480UK